Phase 3 N=420 Sarilumab COVID-19
Corona Virus Infection
Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points — 10.0; 10.0; 12.0 days — p=0.9561
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,312 Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Corona Virus Infection · Acute Respiratory Distress Syndrome · SARS-CoV Infection
Primary: Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline — 49; 58 Participants — p=0.35
Phase 3 N=511 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia
Primary: Survival Without BPD at 36 Weeks Post Menstrual Age. — 79; 82 Participants — p=0.89
Phase 3 N=13 Cardiovascular Effects of Racemic Epinephrine Pellets
Epinephrine Causing Adverse Effects in Therapeutic Use
Primary: Cardiovascular Outcomes — 91.5; 93.4 Beats Per Minute
Phase 3 N=280 A Study for Patients Who Completed VITALITY-ALS (CY 4031)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Participants With Adverse Events — 112; 157 Participants
Phase 3 N=249 An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) — -0.17; -0.85; -0.26; -1.06 Sore on a scale
Phase 3 N=213 An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment — 66; 70; 0 Participants
Phase 3 N=507 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 — 0.06; -0.70 percentage HbA1c — p=< 0.0001
Phase 3 N=518 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 — -0.29; -0.77 percentage of HbA1c — p=< 0.0001
Phase 3 N=571 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 — -0.27; -0.72; -0.81 percentage of HbA1c — p=<0.0001
Phase 3 N=108 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With an Observer Rating of Successful Participant Self-administration — 100; 100 percentage of participants
Phase 3 N=770 Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26 — -0.7; -0.8; -0.3 percentage of HbA1c — p=< 0.0001
Phase 3 N=140 Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH
Dentin Hypersensitivity
Primary: Percent Change in Mean Score of Pain Response From Baseline on Schiff Cold Air Sensitivity Scale Using Air Blast Stimulus — 18; 45; 37; 15 percentage of change in mean…
Phase 3 N=301 Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Glabellar Frown Lines
Primary: Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo — 142; 0 Participants
Phase 3 N=954 Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c at Week 52 — -0.40; -0.65; -0.49; -0.61 percentage of HbA1c — p=0.3306